SlideShare a Scribd company logo
Bis(indolyl) ketohydrazide-hydrazones: Identification of
Potent and Selective Novel Tubulin Inhibitors
Reyna Valdez1, Mukund Tantak2, Dalip Kumar2 and Rachna Sadana1
1Department of Natural Sciences, UHD,
2 Department of Chemistry, Birla Institute of Technology and Science, India
Abstract
Cancer is a collection of diseases hallmarked by uncontrolled cell division.
Cancer treatment involves varying combinations of surgery, radiation,
chemotherapy and hormone therapy. Chemotherapy employs the use of drugs that
kill the rapidly dividing cells (characteristic of cancer cells). Various
chemotherapeutic drugs such as paclitaxel and vinblastine interrupt cell division by
binding to tubulin (a protein responsible for spindle formation, a critical step in
cell division). For more than 50 years, tubulin binding drugs have been used to
treat cancer, Scientists are still in search of novel anti-cancer compounds targeting
tubulin for two reasons; (1) patients develop resistance to existing drugs and (2)
tubulin is one of the most validated targets for cancer treatment. Eighteen
analogues of coscinamides were screened for their cytotoxic effects on 5 different
cancer cell lines. Our initial screen identified three compounds that caused cell
death with IC50 less than 1µM. Our data indicates that the most active compounds
TMCOS-3, TMCOS-6 and TMCOS-11 induced apoptotic cell death in JURKATs
when DNA fragmentation and Caspase3/7 activation were used as apoptotic
marker assays. TMCOS-11 exerts its anti-cell proliferation activity through
inhibition of tubulin polymerization (IC50 = 20 nM) and TMCOS-11 treated cells
are stuck in G2/M phase when analyzed by flow cytometry.
Introduction
Cancer is the second leading cause of deaths in the United States, and the
number of people diagnosed with cancer continues to increase every year (1).
Chemotherapy is the most commonly used regimen once cancer has spread
throughout the body. Chemotherapy drugs target rapidly dividing cells, and are
cytotoxic or cytostatic. The best results are obtained by killing cancer cells using
cytotoxic drugs rather than impeding their growth by using cytostatic drugs,
because this leave the cancer cells in a viable state. Vinca alkaloids (vinblastine)
and taxanes (paclitaxel), are commonly used anti-cancer drugs, they target tubulin,
a protein responsible for spindle organization in cell division. Although
chemotherapy has been utilized as a method for the treatment of cancer since 1940
(2), scientists are still in search of novel cytotoxic compounds because of
development of drug resistance in cancer patients, which can lead to chemotherapy
failure.
The most commonly used strategy to develop a drug involves identification
and validation of a target, selection of a lead compound form a library of
compounds by random screening, modifying the lead compound to optimize its
effects and finally, clinical trials.
Here in this study, we screened eighteen new synthetic compounds for their
cytotoxicity on five different cancer cell lines, and mechanism of cell death.
Methods
1. Mammalian Cell Culture: HCT-116, MDA-MB-231, and MCF7 cells were
maintained in DMEM complete growth media containing 10% FBS and
antibiotics (penicillin/ streptomycin), and Jurkat cells were maintained in RPMI
media with FBS and antibiotics.
2. MTT Assay: 4000-5000 cells per well seeded in a 96-well plate and MTT assay
was performed in the absence and presence of varying concentration of
compounds tested using a kit from abcam.
3. DNA Isolation: 6 X 105 cells were seeded on 35 mm dish and treated with
various compounds. Genomic DNA was isolated using a kit from abcam.
4. In Vitro Tubulin Polymeryzation: A fluorescence based assay was used to
monitor the tubulin polymerization in absence and presence of cytotoxic
compounds. A kit was purchased from Cytoskeleton Inc.
5. Caspase Assay: 100,000 cells per well were seeded in a 24-well plate in 0.5
mL media and treated with various compounds for 48 hours. 100 uL of the
sample was taken from respective wells and Caspase 3/7 assay was performed
in a 96-well plate using a commercially available kit from Promega.
6. Flow Cytometry:
Table 1. Summary of IC50 of various compounds on five different cell lines. IC50 of
TMCOS-3, TMCOS-6 and TMCOS-11 was below 0.5 uM for multiple cells lines.
Summary
• TMCOS-1, TMCOS-3, TMCOS-6, TMCOS-7 and were identified as cytotoxic
compounds in the initial screen when tested on 5 different cancer cell lines at 10
uM concentration.
• TMCOS-3, TMCOS-6, TMCOS-7 and TMCOS-11 have IC50 less than 0.5 uM on
multiple cancer cell lines.
• TMCOS-3, TMCOS-6, TMCOS-7 and TMCOS-11 cause apoptotic cell death
when analyzed for DNA Fragmentation as apoptotic marker.
•TMCOS-3, TMCOS-6, and TMCOS-11 induced caspase 3/7 activation in
JURKAT cells, suggesting that this compounds could kill cancer cells by inducing
apoptosis.
•TMCOS-11 inhibits microtubule formation inhibiting cell division.
•TMCOS-11 stopped ~45% of MCF7 cells at G2/M phase of the cell cycle, when
analyzed by flow cytometry.
Future Work:
Acknowledgements:
• Natural Science Department., University of Houston-Downtown.
• ORCA grant from UHD to Dr. Rachna Sadana
References
1. Murphy, S., et al. (2012). Deaths: Preliminary data for 2010. National Vital
Statistics Reports, 60(4), 1-52.
2. (2000). Cancer multidrug resistance. Nature Biotechnology, 18, IT18-IT20.
HTC-116 MDA-MB-231
BT-474 MCF7
Jurkat
Name of
compound
Cell Line
BT-474 MCF-7 MDA-MB-
231
HCT-116 JURKAT
TMCOS-1 N.D. N.D. N.D. N.D. 3.0
TMCOS-3 N.D. 0.53 1.0 0.1 0.5
TMCOS-5 N.D. 2.3 N.D. N.D. N.D.
TMCOS-6 0.11 0.18 0.1 0.04 0.05
TMCOS-7 N.D. 1.1 N.D. 0.25 10.0
TMCOS-11 0.2 0.08 0.05 0.015 0.02
Figure 1. Illustrates the effects of 18 different compounds on cell proliferation of 5
different cancer cell lines (HCT-116, MCF7, MDA-MB-231, BT-474 and JURKAT.
Doxorubicin was used as positive control. TMCOS-3, 6 and 11 were most cytotxic.
Results
Figure 2. JURKAT cells were treated with
various compounds as labeled on the figure
for 48 hrs. Genomic DNA was isolated and
analyzed using agarose gel electrophoresis.
TMCOS-3, 6, 7 and 11 cause cell death via
apoptosis.
Figure 3. Dose-dependent inhibition of
tubulin polymerization by TMCOS-11.
Figure 4. Caspase activation-induced by TMCOS 3, 6, and 11 in
JURKAT cells for 48 hours. Caspase3/7 activation indicates cell
death via apoptosis.
Figure 5. Cell Cyle progression analysis in TMCOS-
11 treated MCF7 cells. a1: cell treated with vehicle,
a2: cells treated with 3 µM colchicine, a3: cells
treated with 3 µM TMCOS-11 for 24 h. b1: graph
representing % of cells in G1, S and G2/M phase. c

More Related Content

What's hot

Chimeric Antigen Receptors (paper with corresponding power point)
Chimeric Antigen Receptors (paper with corresponding power point)Chimeric Antigen Receptors (paper with corresponding power point)
Chimeric Antigen Receptors (paper with corresponding power point)
Kevin B Hugins
 
Study on Drug Resistance Mediated by Expression of HER-2 and LRP in Tumor Tis...
Study on Drug Resistance Mediated by Expression of HER-2 and LRP in Tumor Tis...Study on Drug Resistance Mediated by Expression of HER-2 and LRP in Tumor Tis...
Study on Drug Resistance Mediated by Expression of HER-2 and LRP in Tumor Tis...
ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY
 
Vorinostat combined with DNMTi epigenetically controls the proliferation of l...
Vorinostat combined with DNMTi epigenetically controls the proliferation of l...Vorinostat combined with DNMTi epigenetically controls the proliferation of l...
Vorinostat combined with DNMTi epigenetically controls the proliferation of l...
MustafaFathy6
 
First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...
First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...
First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...
Prof. Eric Raymond Oncologie Medicale
 
Drug Repurposing Against Infectious Diseases
Drug Repurposing Against Infectious Diseases Drug Repurposing Against Infectious Diseases
Drug Repurposing Against Infectious Diseases
Philip Bourne
 
Samuel Dugger FGF8b Final Report
Samuel Dugger FGF8b Final ReportSamuel Dugger FGF8b Final Report
Samuel Dugger FGF8b Final Report
Samuel Dugger
 
Anti- Tumor assay / Screening of Anticancer Drugs
Anti- Tumor assay / Screening of Anticancer DrugsAnti- Tumor assay / Screening of Anticancer Drugs
Anti- Tumor assay / Screening of Anticancer Drugs
Pratik Parikh
 
MA et al. 2017_SciReps
MA et al. 2017_SciRepsMA et al. 2017_SciReps
MA et al. 2017_SciReps
Dennis Ma
 
biochem of cancer modified dialysis treatment
biochem of cancer modified dialysis treatmentbiochem of cancer modified dialysis treatment
biochem of cancer modified dialysis treatment
Thomas Brinkman
 
[14796813 journal of molecular endocrinology] identification of tacc1, nov,...
[14796813   journal of molecular endocrinology] identification of tacc1, nov,...[14796813   journal of molecular endocrinology] identification of tacc1, nov,...
[14796813 journal of molecular endocrinology] identification of tacc1, nov,...
University of Zambia, School of Pharmacy, Lusaka, Zambia
 
Cancer research
Cancer researchCancer research
Cancer research
David Park
 
Ruta graveolens extract induces dna damage pathways and blocks akt activation...
Ruta graveolens extract induces dna damage pathways and blocks akt activation...Ruta graveolens extract induces dna damage pathways and blocks akt activation...
Ruta graveolens extract induces dna damage pathways and blocks akt activation...
Tiensae Teshome
 
Maslak p.g.-et-al.-2010-blood
Maslak p.g.-et-al.-2010-bloodMaslak p.g.-et-al.-2010-blood
Maslak p.g.-et-al.-2010-blood
SellasCorp
 
ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grad...
ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grad...ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grad...
ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grad...
Enrique Moreno Gonzalez
 
Review of Adoptive T-Cell Immunotherapy
Review of Adoptive T-Cell ImmunotherapyReview of Adoptive T-Cell Immunotherapy
Review of Adoptive T-Cell Immunotherapy
Luke Brennan
 
P1-01-17_poster
P1-01-17_posterP1-01-17_poster
P1-01-17_poster
Amanda Chargin
 
Cellular Therapy in Acute Myeloid Leukemia
Cellular Therapy in Acute Myeloid LeukemiaCellular Therapy in Acute Myeloid Leukemia
Cellular Therapy in Acute Myeloid Leukemia
spa718
 
phd paper
phd paperphd paper
phd paper
Akhilesh Rawat
 
Array_nmeth.3507
Array_nmeth.3507Array_nmeth.3507
Array_nmeth.3507
Aana Hahn
 

What's hot (19)

Chimeric Antigen Receptors (paper with corresponding power point)
Chimeric Antigen Receptors (paper with corresponding power point)Chimeric Antigen Receptors (paper with corresponding power point)
Chimeric Antigen Receptors (paper with corresponding power point)
 
Study on Drug Resistance Mediated by Expression of HER-2 and LRP in Tumor Tis...
Study on Drug Resistance Mediated by Expression of HER-2 and LRP in Tumor Tis...Study on Drug Resistance Mediated by Expression of HER-2 and LRP in Tumor Tis...
Study on Drug Resistance Mediated by Expression of HER-2 and LRP in Tumor Tis...
 
Vorinostat combined with DNMTi epigenetically controls the proliferation of l...
Vorinostat combined with DNMTi epigenetically controls the proliferation of l...Vorinostat combined with DNMTi epigenetically controls the proliferation of l...
Vorinostat combined with DNMTi epigenetically controls the proliferation of l...
 
First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...
First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...
First-in-Human Chimeric antigen receptor (CAR) T cell Therapies: Promises and...
 
Drug Repurposing Against Infectious Diseases
Drug Repurposing Against Infectious Diseases Drug Repurposing Against Infectious Diseases
Drug Repurposing Against Infectious Diseases
 
Samuel Dugger FGF8b Final Report
Samuel Dugger FGF8b Final ReportSamuel Dugger FGF8b Final Report
Samuel Dugger FGF8b Final Report
 
Anti- Tumor assay / Screening of Anticancer Drugs
Anti- Tumor assay / Screening of Anticancer DrugsAnti- Tumor assay / Screening of Anticancer Drugs
Anti- Tumor assay / Screening of Anticancer Drugs
 
MA et al. 2017_SciReps
MA et al. 2017_SciRepsMA et al. 2017_SciReps
MA et al. 2017_SciReps
 
biochem of cancer modified dialysis treatment
biochem of cancer modified dialysis treatmentbiochem of cancer modified dialysis treatment
biochem of cancer modified dialysis treatment
 
[14796813 journal of molecular endocrinology] identification of tacc1, nov,...
[14796813   journal of molecular endocrinology] identification of tacc1, nov,...[14796813   journal of molecular endocrinology] identification of tacc1, nov,...
[14796813 journal of molecular endocrinology] identification of tacc1, nov,...
 
Cancer research
Cancer researchCancer research
Cancer research
 
Ruta graveolens extract induces dna damage pathways and blocks akt activation...
Ruta graveolens extract induces dna damage pathways and blocks akt activation...Ruta graveolens extract induces dna damage pathways and blocks akt activation...
Ruta graveolens extract induces dna damage pathways and blocks akt activation...
 
Maslak p.g.-et-al.-2010-blood
Maslak p.g.-et-al.-2010-bloodMaslak p.g.-et-al.-2010-blood
Maslak p.g.-et-al.-2010-blood
 
ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grad...
ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grad...ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grad...
ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grad...
 
Review of Adoptive T-Cell Immunotherapy
Review of Adoptive T-Cell ImmunotherapyReview of Adoptive T-Cell Immunotherapy
Review of Adoptive T-Cell Immunotherapy
 
P1-01-17_poster
P1-01-17_posterP1-01-17_poster
P1-01-17_poster
 
Cellular Therapy in Acute Myeloid Leukemia
Cellular Therapy in Acute Myeloid LeukemiaCellular Therapy in Acute Myeloid Leukemia
Cellular Therapy in Acute Myeloid Leukemia
 
phd paper
phd paperphd paper
phd paper
 
Array_nmeth.3507
Array_nmeth.3507Array_nmeth.3507
Array_nmeth.3507
 

Viewers also liked

14 west concepts lm gabrish
14 west concepts lm gabrish14 west concepts lm gabrish
14 west concepts lm gabrish
Lisa Gabrish
 
dane_mcmillan August 2015 CV
dane_mcmillan August 2015 CVdane_mcmillan August 2015 CV
dane_mcmillan August 2015 CV
Dane McMillan
 
徐伟简历-应聘销售工程师
徐伟简历-应聘销售工程师徐伟简历-应聘销售工程师
徐伟简历-应聘销售工程师Jimmy ??
 
Text romeo and juliet
Text romeo and julietText romeo and juliet
Text romeo and julietsylviadriana
 
technical sheet supply chain earth
technical sheet supply chain earthtechnical sheet supply chain earth
technical sheet supply chain earth
libnam
 
Star image
Star imageStar image
Star image
abbierose
 
Dual screem browser
Dual screem browserDual screem browser
Dual screem browser
ArletGlz
 
080718 Liberty Alliance Technical Seminar
080718 Liberty Alliance Technical Seminar080718 Liberty Alliance Technical Seminar
080718 Liberty Alliance Technical Seminar
Hiroki Itoh
 
Dinamica microtaller
Dinamica microtallerDinamica microtaller
Dinamica microtaller
MARIAALCIRAHUAYANRIOS
 
Ying's CV
Ying's CVYing's CV
Ying's CV
Calvin Cheung
 
Virus informáticos
Virus informáticosVirus informáticos
Virus informáticos
marcepati13
 
Utah State University Biology and Natural Resources Renovation
Utah State University Biology and Natural Resources RenovationUtah State University Biology and Natural Resources Renovation
Utah State University Biology and Natural Resources Renovation
HigherEdUtah
 
Puedo mejorar mi rendimiento escolar
Puedo mejorar mi rendimiento escolarPuedo mejorar mi rendimiento escolar
Puedo mejorar mi rendimiento escolar
Clarita Ascate Mego
 
Diversity, Inclusion and the Learning, Speaking Body in the Empty Space
Diversity, Inclusion and the Learning, Speaking Body in the Empty SpaceDiversity, Inclusion and the Learning, Speaking Body in the Empty Space
Diversity, Inclusion and the Learning, Speaking Body in the Empty Space
Susan Hillyard
 
Puedo comunicarme mejor
Puedo comunicarme mejorPuedo comunicarme mejor
Puedo comunicarme mejor
mil61
 
Organizo mi tiempo libre
Organizo mi tiempo libreOrganizo mi tiempo libre
Organizo mi tiempo libre
KAtiRojChu
 

Viewers also liked (18)

14 west concepts lm gabrish
14 west concepts lm gabrish14 west concepts lm gabrish
14 west concepts lm gabrish
 
dane_mcmillan August 2015 CV
dane_mcmillan August 2015 CVdane_mcmillan August 2015 CV
dane_mcmillan August 2015 CV
 
徐伟简历-应聘销售工程师
徐伟简历-应聘销售工程师徐伟简历-应聘销售工程师
徐伟简历-应聘销售工程师
 
Text romeo and juliet
Text romeo and julietText romeo and juliet
Text romeo and juliet
 
technical sheet supply chain earth
technical sheet supply chain earthtechnical sheet supply chain earth
technical sheet supply chain earth
 
Star image
Star imageStar image
Star image
 
Dual screem browser
Dual screem browserDual screem browser
Dual screem browser
 
080718 Liberty Alliance Technical Seminar
080718 Liberty Alliance Technical Seminar080718 Liberty Alliance Technical Seminar
080718 Liberty Alliance Technical Seminar
 
Dinamica microtaller
Dinamica microtallerDinamica microtaller
Dinamica microtaller
 
Blog คืออะไร
Blog คืออะไรBlog คืออะไร
Blog คืออะไร
 
Ying's CV
Ying's CVYing's CV
Ying's CV
 
Virus informáticos
Virus informáticosVirus informáticos
Virus informáticos
 
Utah State University Biology and Natural Resources Renovation
Utah State University Biology and Natural Resources RenovationUtah State University Biology and Natural Resources Renovation
Utah State University Biology and Natural Resources Renovation
 
Puedo mejorar mi rendimiento escolar
Puedo mejorar mi rendimiento escolarPuedo mejorar mi rendimiento escolar
Puedo mejorar mi rendimiento escolar
 
Diversity, Inclusion and the Learning, Speaking Body in the Empty Space
Diversity, Inclusion and the Learning, Speaking Body in the Empty SpaceDiversity, Inclusion and the Learning, Speaking Body in the Empty Space
Diversity, Inclusion and the Learning, Speaking Body in the Empty Space
 
touya m
touya mtouya m
touya m
 
Puedo comunicarme mejor
Puedo comunicarme mejorPuedo comunicarme mejor
Puedo comunicarme mejor
 
Organizo mi tiempo libre
Organizo mi tiempo libreOrganizo mi tiempo libre
Organizo mi tiempo libre
 

Similar to SRC TMCOS 2015 2

Voss et al. - 2006 - Identification of potent anticancer activity in Xi
Voss et al. - 2006 - Identification of potent anticancer activity in XiVoss et al. - 2006 - Identification of potent anticancer activity in Xi
Voss et al. - 2006 - Identification of potent anticancer activity in Xi
Cristina Voss
 
Anticancer drug screening
Anticancer drug screeningAnticancer drug screening
Anticancer drug screening
shishirkawde
 
Role of cancer stem cells in cancer therapy
Role of cancer stem cells in cancer therapyRole of cancer stem cells in cancer therapy
Role of cancer stem cells in cancer therapy
niper hyd
 
Suppress lung cancer progression via up regulation of linc rna-p21
Suppress lung cancer progression via up regulation of linc rna-p21Suppress lung cancer progression via up regulation of linc rna-p21
Suppress lung cancer progression via up regulation of linc rna-p21
Clinical Surgery Research Communications
 
PlOSone paper
PlOSone paperPlOSone paper
PlOSone paper
Naomi McReynolds
 
IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...
IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...
IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...
Jing Zang
 
Preclinical trial for Anticancer drugs
Preclinical trial for Anticancer drugsPreclinical trial for Anticancer drugs
Preclinical trial for Anticancer drugs
Sanaspriya01
 
Cancer stem cells &new therapeutics methods
Cancer stem cells &new therapeutics methodsCancer stem cells &new therapeutics methods
Cancer stem cells &new therapeutics methods
mahdi hatami
 
Comprehensivereportcannabisextractmovement 131014094154-phpapp01
Comprehensivereportcannabisextractmovement 131014094154-phpapp01Comprehensivereportcannabisextractmovement 131014094154-phpapp01
Comprehensivereportcannabisextractmovement 131014094154-phpapp01
Jeremy Dupuis
 
Comprehensive Report on The Cannabis Extract Movement
Comprehensive Report on The Cannabis Extract MovementComprehensive Report on The Cannabis Extract Movement
Comprehensive Report on The Cannabis Extract Movement
Debra Ulrich
 
Nucl_Acids_Res-2015-Yang-NAR_gkv060
Nucl_Acids_Res-2015-Yang-NAR_gkv060Nucl_Acids_Res-2015-Yang-NAR_gkv060
Nucl_Acids_Res-2015-Yang-NAR_gkv060
Bing Yang
 
MOLECULAR AND CLINICAL ONCOLOGY 2 1016-10221016Abstract.docx
MOLECULAR AND CLINICAL ONCOLOGY  2  1016-10221016Abstract.docxMOLECULAR AND CLINICAL ONCOLOGY  2  1016-10221016Abstract.docx
MOLECULAR AND CLINICAL ONCOLOGY 2 1016-10221016Abstract.docx
gilpinleeanna
 
scd%2E2014%2E0405
scd%2E2014%2E0405scd%2E2014%2E0405
scd%2E2014%2E0405
Artem Trotsyuk
 
inducing Apoptosis in cancer cell by natural compounds and screening methods
inducing Apoptosis in cancer cell by natural compounds and screening methodsinducing Apoptosis in cancer cell by natural compounds and screening methods
inducing Apoptosis in cancer cell by natural compounds and screening methods
syeddastagir9
 
SCLC CTC paper 2014
SCLC CTC paper 2014SCLC CTC paper 2014
SCLC CTC paper 2014
Sitta Sittampalam
 
Final STAT3 Manuscript
Final STAT3 ManuscriptFinal STAT3 Manuscript
Final STAT3 Manuscript
Alex Engar
 
Plos
PlosPlos
SCREENING OF ANTI CANCER DRUGS
SCREENING OF ANTI CANCER DRUGSSCREENING OF ANTI CANCER DRUGS
SCREENING OF ANTI CANCER DRUGS
Rafa Zubair
 
Chemotherapeutic Drug Primed Stem Cells
Chemotherapeutic Drug Primed Stem CellsChemotherapeutic Drug Primed Stem Cells
Chemotherapeutic Drug Primed Stem Cells
Garry McDowell
 

Similar to SRC TMCOS 2015 2 (19)

Voss et al. - 2006 - Identification of potent anticancer activity in Xi
Voss et al. - 2006 - Identification of potent anticancer activity in XiVoss et al. - 2006 - Identification of potent anticancer activity in Xi
Voss et al. - 2006 - Identification of potent anticancer activity in Xi
 
Anticancer drug screening
Anticancer drug screeningAnticancer drug screening
Anticancer drug screening
 
Role of cancer stem cells in cancer therapy
Role of cancer stem cells in cancer therapyRole of cancer stem cells in cancer therapy
Role of cancer stem cells in cancer therapy
 
Suppress lung cancer progression via up regulation of linc rna-p21
Suppress lung cancer progression via up regulation of linc rna-p21Suppress lung cancer progression via up regulation of linc rna-p21
Suppress lung cancer progression via up regulation of linc rna-p21
 
PlOSone paper
PlOSone paperPlOSone paper
PlOSone paper
 
IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...
IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...
IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...
 
Preclinical trial for Anticancer drugs
Preclinical trial for Anticancer drugsPreclinical trial for Anticancer drugs
Preclinical trial for Anticancer drugs
 
Cancer stem cells &new therapeutics methods
Cancer stem cells &new therapeutics methodsCancer stem cells &new therapeutics methods
Cancer stem cells &new therapeutics methods
 
Comprehensivereportcannabisextractmovement 131014094154-phpapp01
Comprehensivereportcannabisextractmovement 131014094154-phpapp01Comprehensivereportcannabisextractmovement 131014094154-phpapp01
Comprehensivereportcannabisextractmovement 131014094154-phpapp01
 
Comprehensive Report on The Cannabis Extract Movement
Comprehensive Report on The Cannabis Extract MovementComprehensive Report on The Cannabis Extract Movement
Comprehensive Report on The Cannabis Extract Movement
 
Nucl_Acids_Res-2015-Yang-NAR_gkv060
Nucl_Acids_Res-2015-Yang-NAR_gkv060Nucl_Acids_Res-2015-Yang-NAR_gkv060
Nucl_Acids_Res-2015-Yang-NAR_gkv060
 
MOLECULAR AND CLINICAL ONCOLOGY 2 1016-10221016Abstract.docx
MOLECULAR AND CLINICAL ONCOLOGY  2  1016-10221016Abstract.docxMOLECULAR AND CLINICAL ONCOLOGY  2  1016-10221016Abstract.docx
MOLECULAR AND CLINICAL ONCOLOGY 2 1016-10221016Abstract.docx
 
scd%2E2014%2E0405
scd%2E2014%2E0405scd%2E2014%2E0405
scd%2E2014%2E0405
 
inducing Apoptosis in cancer cell by natural compounds and screening methods
inducing Apoptosis in cancer cell by natural compounds and screening methodsinducing Apoptosis in cancer cell by natural compounds and screening methods
inducing Apoptosis in cancer cell by natural compounds and screening methods
 
SCLC CTC paper 2014
SCLC CTC paper 2014SCLC CTC paper 2014
SCLC CTC paper 2014
 
Final STAT3 Manuscript
Final STAT3 ManuscriptFinal STAT3 Manuscript
Final STAT3 Manuscript
 
Plos
PlosPlos
Plos
 
SCREENING OF ANTI CANCER DRUGS
SCREENING OF ANTI CANCER DRUGSSCREENING OF ANTI CANCER DRUGS
SCREENING OF ANTI CANCER DRUGS
 
Chemotherapeutic Drug Primed Stem Cells
Chemotherapeutic Drug Primed Stem CellsChemotherapeutic Drug Primed Stem Cells
Chemotherapeutic Drug Primed Stem Cells
 

SRC TMCOS 2015 2

  • 1. Bis(indolyl) ketohydrazide-hydrazones: Identification of Potent and Selective Novel Tubulin Inhibitors Reyna Valdez1, Mukund Tantak2, Dalip Kumar2 and Rachna Sadana1 1Department of Natural Sciences, UHD, 2 Department of Chemistry, Birla Institute of Technology and Science, India Abstract Cancer is a collection of diseases hallmarked by uncontrolled cell division. Cancer treatment involves varying combinations of surgery, radiation, chemotherapy and hormone therapy. Chemotherapy employs the use of drugs that kill the rapidly dividing cells (characteristic of cancer cells). Various chemotherapeutic drugs such as paclitaxel and vinblastine interrupt cell division by binding to tubulin (a protein responsible for spindle formation, a critical step in cell division). For more than 50 years, tubulin binding drugs have been used to treat cancer, Scientists are still in search of novel anti-cancer compounds targeting tubulin for two reasons; (1) patients develop resistance to existing drugs and (2) tubulin is one of the most validated targets for cancer treatment. Eighteen analogues of coscinamides were screened for their cytotoxic effects on 5 different cancer cell lines. Our initial screen identified three compounds that caused cell death with IC50 less than 1µM. Our data indicates that the most active compounds TMCOS-3, TMCOS-6 and TMCOS-11 induced apoptotic cell death in JURKATs when DNA fragmentation and Caspase3/7 activation were used as apoptotic marker assays. TMCOS-11 exerts its anti-cell proliferation activity through inhibition of tubulin polymerization (IC50 = 20 nM) and TMCOS-11 treated cells are stuck in G2/M phase when analyzed by flow cytometry. Introduction Cancer is the second leading cause of deaths in the United States, and the number of people diagnosed with cancer continues to increase every year (1). Chemotherapy is the most commonly used regimen once cancer has spread throughout the body. Chemotherapy drugs target rapidly dividing cells, and are cytotoxic or cytostatic. The best results are obtained by killing cancer cells using cytotoxic drugs rather than impeding their growth by using cytostatic drugs, because this leave the cancer cells in a viable state. Vinca alkaloids (vinblastine) and taxanes (paclitaxel), are commonly used anti-cancer drugs, they target tubulin, a protein responsible for spindle organization in cell division. Although chemotherapy has been utilized as a method for the treatment of cancer since 1940 (2), scientists are still in search of novel cytotoxic compounds because of development of drug resistance in cancer patients, which can lead to chemotherapy failure. The most commonly used strategy to develop a drug involves identification and validation of a target, selection of a lead compound form a library of compounds by random screening, modifying the lead compound to optimize its effects and finally, clinical trials. Here in this study, we screened eighteen new synthetic compounds for their cytotoxicity on five different cancer cell lines, and mechanism of cell death. Methods 1. Mammalian Cell Culture: HCT-116, MDA-MB-231, and MCF7 cells were maintained in DMEM complete growth media containing 10% FBS and antibiotics (penicillin/ streptomycin), and Jurkat cells were maintained in RPMI media with FBS and antibiotics. 2. MTT Assay: 4000-5000 cells per well seeded in a 96-well plate and MTT assay was performed in the absence and presence of varying concentration of compounds tested using a kit from abcam. 3. DNA Isolation: 6 X 105 cells were seeded on 35 mm dish and treated with various compounds. Genomic DNA was isolated using a kit from abcam. 4. In Vitro Tubulin Polymeryzation: A fluorescence based assay was used to monitor the tubulin polymerization in absence and presence of cytotoxic compounds. A kit was purchased from Cytoskeleton Inc. 5. Caspase Assay: 100,000 cells per well were seeded in a 24-well plate in 0.5 mL media and treated with various compounds for 48 hours. 100 uL of the sample was taken from respective wells and Caspase 3/7 assay was performed in a 96-well plate using a commercially available kit from Promega. 6. Flow Cytometry: Table 1. Summary of IC50 of various compounds on five different cell lines. IC50 of TMCOS-3, TMCOS-6 and TMCOS-11 was below 0.5 uM for multiple cells lines. Summary • TMCOS-1, TMCOS-3, TMCOS-6, TMCOS-7 and were identified as cytotoxic compounds in the initial screen when tested on 5 different cancer cell lines at 10 uM concentration. • TMCOS-3, TMCOS-6, TMCOS-7 and TMCOS-11 have IC50 less than 0.5 uM on multiple cancer cell lines. • TMCOS-3, TMCOS-6, TMCOS-7 and TMCOS-11 cause apoptotic cell death when analyzed for DNA Fragmentation as apoptotic marker. •TMCOS-3, TMCOS-6, and TMCOS-11 induced caspase 3/7 activation in JURKAT cells, suggesting that this compounds could kill cancer cells by inducing apoptosis. •TMCOS-11 inhibits microtubule formation inhibiting cell division. •TMCOS-11 stopped ~45% of MCF7 cells at G2/M phase of the cell cycle, when analyzed by flow cytometry. Future Work: Acknowledgements: • Natural Science Department., University of Houston-Downtown. • ORCA grant from UHD to Dr. Rachna Sadana References 1. Murphy, S., et al. (2012). Deaths: Preliminary data for 2010. National Vital Statistics Reports, 60(4), 1-52. 2. (2000). Cancer multidrug resistance. Nature Biotechnology, 18, IT18-IT20. HTC-116 MDA-MB-231 BT-474 MCF7 Jurkat Name of compound Cell Line BT-474 MCF-7 MDA-MB- 231 HCT-116 JURKAT TMCOS-1 N.D. N.D. N.D. N.D. 3.0 TMCOS-3 N.D. 0.53 1.0 0.1 0.5 TMCOS-5 N.D. 2.3 N.D. N.D. N.D. TMCOS-6 0.11 0.18 0.1 0.04 0.05 TMCOS-7 N.D. 1.1 N.D. 0.25 10.0 TMCOS-11 0.2 0.08 0.05 0.015 0.02 Figure 1. Illustrates the effects of 18 different compounds on cell proliferation of 5 different cancer cell lines (HCT-116, MCF7, MDA-MB-231, BT-474 and JURKAT. Doxorubicin was used as positive control. TMCOS-3, 6 and 11 were most cytotxic. Results Figure 2. JURKAT cells were treated with various compounds as labeled on the figure for 48 hrs. Genomic DNA was isolated and analyzed using agarose gel electrophoresis. TMCOS-3, 6, 7 and 11 cause cell death via apoptosis. Figure 3. Dose-dependent inhibition of tubulin polymerization by TMCOS-11. Figure 4. Caspase activation-induced by TMCOS 3, 6, and 11 in JURKAT cells for 48 hours. Caspase3/7 activation indicates cell death via apoptosis. Figure 5. Cell Cyle progression analysis in TMCOS- 11 treated MCF7 cells. a1: cell treated with vehicle, a2: cells treated with 3 µM colchicine, a3: cells treated with 3 µM TMCOS-11 for 24 h. b1: graph representing % of cells in G1, S and G2/M phase. c